By Business Wire –
Junevity, a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases, today announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.
Founded by a team of experts in aging biology, machine learning and drug development and based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF. Junevity’s RESET platform uses large-scale human data and AI to identify novel transcription factor targets and repress them with siRNA. Initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous indications.
